Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein

British Journal of Pharmacology

Volumn 134, Issue 8, 2001, Pages 1609-1618

  Taylor, Andrew M ^a   Storm, Janet ^a   Soceneantu, Loredana ^a   Linton, Kenneth J ^b   Gabriel, Mark ^a   Martin, Catherine ^a   Woodhouse, James ^a   Blott, Emma ^a   Higgins, Christopher F ^b   Callaghan, Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

ABC transporter; ATP hydrolysis; Cysteine scanning mutagenesis; Drug binding; P glycoprotein; Purification and reconstitution; Recombinant expression; Trichoplusia ni (High Five) cells

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ANTHRANILIC ACID DERIVATIVE; AZIDOPINE; CYSTEINE; GLYCOPROTEIN P; NICARDIPINE; SERINE; VINBLASTINE; XR 9756;

AMINO ACID SUBSTITUTION; ARTICLE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HYDROLYSIS; MICHAELIS MENTEN KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANIMALS; AZIDES; BACULOVIRIDAE; BINDING SITES; CELL MEMBRANE; CELLS, CULTURED; CROSS-LINKING REAGENTS; CYSTEINE; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MUTAGENESIS; NICARDIPINE; P-GLYCOPROTEIN; PHOTOAFFINITY LABELS; SERINE; SPODOPTERA; VINBLASTINE;

EID: 0035674849     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704400     Document Type: Article

References (45)

1. Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein
2. Covalent inhibitors of P-glycoprotein ATPase activity
3. Assay of proteins in the presence of interfering materials
4. Cysteine-scanning mutagenesis provides no evidence for the extracellular accessibility of the nucleotide-binding domains of the multidrug resistance transporter P-glycoprotein
5. Characterization of the azidopine and vinblastine binding site of P-glycoprotein
6. In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity
7. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: Application to lens ATPases
8. Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves
9. P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca-alkaloid-selective binding site
10. Cys-scanning mutagenesis: A novel approach to structure function relationships in polytopic membrane proteins
11. Resolving the structure of the Ca2+ channel by photoaffinity labeling
12. Major photoaffinity drug labeling sites for iodaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12
13. Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system
14. ABC transporters: From microorganisms to man
15. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport
16. Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein
17. Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates
18. Cleavage of structural proteins during the assembly of the head of bactgeriophage T4
19. Transmembrane topography of the 100-kDa a subunit (Vphlp) of the yeast vacuolar proton-translocating ATPase
20. Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity
21. Membrane topology of a cysteine-less mutant of human P-glycoprotein
22. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using MTS-verapamil
23. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction
24. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein
25. Communication between multiple drug binding sites on P-glycoprotein
26. Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis
27. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody
28. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene
29. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma
30. Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein
31. Histidine 225, a residue of the NhaA-Na+/H+ antiporter of Escherichia coli is exposed and faces the cell exterior
32. Selection of recombinant baculoviruses by visual screening
33. Clinical trials of agents that reverse multidrug resistance. A literature review
34. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state
35. Mechanisms of membrane protein insertion into liposomes during reconstitution procedures involving the use of detergents. 2. Incorporation of the light-driven proton pump bacteriorhodopsin
36. The alpha 1-adrenergic photoaffinity probe [125I]aryla-zidoprazosin binds to a specific peptide of P-glycoprotein in multidrug-resistant cells
37. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers
38. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells
39. Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein
40. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells
41. Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between the two nucleotide-binding sites in human P-glycoprotein
42. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site
43. Construction of a functional lactose permease devoid of cysteine residues
44. Dissection of drug-binding-induced conformational changes in P-glycoprotein
45. The yeast mitochondrial citrate transport protein. Probing the roles of cysteines, Arg(181), and Arg(189) in transporter function